Kalvista Pharm Stock Price, News & Analysis

KalVista Pharmaceuticals (NASDAQ: KALV) announced the acceptance of six scientific abstracts for presentation at the European Academy of Allergy and Clinical Immunology Congress 2025 in Glasgow, UK (June 13-16, 2025). The presentations focus on sebetralstat and hereditary angioedema (HAE) treatments, including data on psychological burden, treatment adherence, and attack management. Key presentations include interim analysis from KONFIDENT-S study on sebetralstat's effectiveness in HAE attack treatment, studies on treatment-related anxiety, and impact of delayed HAE attack treatment. Additionally, KalVista will sponsor a healthcare professional symposium titled "Closing Gaps in HAE Management" on June 14, featuring international experts discussing HAE patient control.

KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of inducement stock options to five newly-hired employees. The compensation committee approved options to purchase a total of 50,000 shares of KalVista common stock, with the exercise price set at the closing price on June 1, 2025. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years, contingent on continued employment. The 10-year term options were granted under KalVista's Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).

KalVista Pharmaceuticals presented new data for sebetralstat, their oral treatment for hereditary angioedema (HAE) attacks, at two major medical congresses. The drug demonstrated consistent efficacy across both KONFIDENT and KONFIDENT-S trials, halting attack progression in a median time of 19.8 minutes. For mucosal attacks, patients could self-administer quickly (20 minutes for abdominal, 11.5 minutes for laryngeal attacks), with symptom relief beginning at 1.3 hours. The drug proved effective even for severe attacks, showing symptom relief in 1.36 hours when treatment was delayed. Notably, 96% of attacks reaching symptom relief within 12 hours did so without needing additional sebetralstat doses. The drug maintained a favorable safety profile, particularly important for laryngeal attacks where swallowing difficulties could be concerning.

KalVista Pharmaceuticals (NASDAQ: KALV) announced its participation in a fireside chat at the Jefferies Global Healthcare Conference. The presentation is scheduled for Thursday, June 5, 2025, at 8:45 a.m. ET. Investors and interested parties can access a live webcast of the presentation through KalVista's website at www.kalvista.com. The audio recording will remain available on the company's website for 30 days following the presentation.

KalVista Pharmaceuticals (NASDAQ: KALV) has announced the granting of inducement stock options to three newly-hired employees. The compensation committee approved options to purchase a total of 14,000 shares of KalVista common stock on May 1, 2025. The exercise price matches the closing price of KALV stock on the grant date. The vesting schedule includes 25% after one year, with the remaining options vesting monthly over three years, contingent on continued employment. The options have a 10-year term and are governed by KalVista's Inducement Equity Incentive Plan, granted under Nasdaq Listing Rule 5635(c)(4).

KalVista Pharmaceuticals (NASDAQ: KALV) has announced its upcoming participation in a fireside chat at the Citizens Life Sciences Conference. The presentation is scheduled for Wednesday, May 7, 2025, at 11:30 a.m. ET.

Interested parties can access a live webcast of the presentation through KalVista's website at www.kalvista.com. For those unable to attend the live session, an audio recording will remain accessible on the company's website for 30 days following the presentation.

KalVista Pharmaceuticals (Nasdaq: KALV) has entered into a licensing agreement with Kaken Pharmaceutical for commercialization rights of sebetralstat in Japan. The deal includes an $11 million upfront payment, potential additional payment of up to $11 million upon achieving regulatory milestone expected in early 2026, plus commercial milestone payments and royalties approximately in the mid-twenties percentage of sales.

Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema (HAE). The drug has received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare, and KalVista has submitted a New Drug Application in Japan. If approved, sebetralstat would become the first oral on-demand treatment for HAE in Japan.

KalVista Pharmaceuticals (NASDAQ: KALV) has granted inducement stock options to ten newly-hired employees. The aggregate grant consists of 87,000 shares of KalVista common stock, issued on April 1, 2025.

The options' exercise price matches KalVista's common stock closing price on the grant date. The vesting schedule includes 25% after one year, with the remaining vesting monthly over three years, contingent on continued employment. The options have a 10-year term and fall under KalVista's Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).

KalVista Pharmaceuticals (NASDAQ: KALV) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company will engage in a fireside chat scheduled for Monday, April 7, 2025, at 1:30 p.m. ET.

The presentation will be accessible through a live webcast on KalVista's official website. Additionally, an audio recording of the presentation will remain available on the company's website for 30 days following the event.